Pioneering click chemistry in humans

Shasqi is leveraging the power of Nobel Prize winning technology, click chemistry, to activate cancer treatments at the site of the tumor. This approach has the potential to expand the therapeutic index of cancer drugs, while enhancing safety and minimizing toxicity.

We are the only company using click chemistry in humans and are rapidly advancing our pipeline with a Phase 2 study in progress for our lead product.

Click Activated Protodrugs Against Cancer (CAPAC™)

CAPAC is a simple, yet incredibly powerful approach designed to minimize toxicity and dramatically enhance the ability of cancer treatments to eliminate tumors. The power behind this platform, Click Chemistry, is a Nobel Prize winning technology in which two compounds ‘click’ together via a chemical reaction, like clicking a seatbelt into a buckle, ignoring everything else around them.

  1. One half of the ‘click’ reagent is localized to the tumor, either through the physical injection of a harmless biopolymer or with the use of antibodies. Either approach keeps the click reagent’s available for several days.
  2. A cancer therapeutic is coupled to the other half of the ‘click’ leading to an attenuated version of the initial drug. This ‘protodrug’ is infused into the body.
  3. The two halves ‘click’ together within the tumor via a simple and elegant chemical reaction, releasing the cancer therapeutic(s) directly into the tumor and the surrounding tumor microenvironment.

Enabling previously unachievable tumor exposure to doxorubucin​

The lead asset, SQ3370, from our first-generation program is in Phase 2 clinical testing. A targeting agent (biopolymer) is directly injected into the tumor, followed by systemic administration of an attenuated form of doxorubicin , which gets activated by click chemistry at the tumor site. During a Phase 1 clinical study of SQ3370 in advanced sarcomas and other solid tumors, patients we re able to receive more than 12 times the conventional dose without experiencing dose limiting toxicities. Preliminary data showed that there was an increase in activated immune cells and signs of tumor cell death on sequential tumor biopsies.

A Phase 2 study of SQ3370 is currently enrolling patients. For more information on our clinical trial please see

Rapidly progressing our product pipeline

While SQ3370 relies on a tumor targeting agent that is directly injected into the tumor, our second generation agents use a targeting agent that is based on a specific antibody. Multiple protodrugs can be paired with various antibodies, making the platform highly modular.​

Shasqi in the media

April 01, 2023

Drug Discovery World talks about the potential of chemistry to engineer biology to improve the effectiveness of human therapeutics and revolutionise the treatment of disease.

March 1, 2023

Ben Comer of Life Science Leader met with Nobel Laureate, and Shasqi Advisor, Carolyn Bertozzi and our CEO, José to talk about how Shasqi is bringing Nobel Prize winning technology to cancer patients

February 23, 2023

Shasqi announces the appointment of industry veteran Jean-Frédéric Viret, PhD as Chief Financial Officer to drive financial strategy for Shasqi platform expansion.

February 8, 2023

Jose sat down with Daniel Levine of The Bio Report podcast about our platform technology, how it works, and why this can lead to safer and more powerful cancer therapies.

Media archive